TY - JOUR
T1 - Current Status of Uterine Leiomyosarcoma in the Tohoku Region
T2 - Results of the Tohoku Translational Center Development Network Survey
AU - Tokunaga, Hideki
AU - Takahashi, Fumiaki
AU - Yamamoto, Hiroki
AU - Honda, Tsuyoshi
AU - Watanabe, Takafumi
AU - Shoji, Tadahiro
AU - Sugiyama, Toru
AU - Yamada, Hidekazu
AU - Tando, Tomoe
AU - Yoshinaga, Kosuke
AU - Kagabu, Satoko
AU - Otsuki, Takeo
AU - Kin, Shogo
AU - Yokoyama, Yoshihito
AU - Wagatsuma, Satoshige
AU - Sato, Kazuyo
AU - Sato, Hirokazu
AU - Oishi, Takashi
AU - Yoshida, Yuji
AU - Hayasaka, Tadashi
AU - Matsui, Toshihiko
AU - Imai, Noriaki
AU - Nishigori, Hidekazu
AU - Shimokawa, Hiroaki
AU - Yaegashi, Nobuo
AU - Watanabe, Yoh
N1 - Publisher Copyright:
© 2017, Japan Society of Clinical Oncology.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background: To prepare for a future clinical trial for improving the long-term prognosis of patients with uterine leiomyosarcoma (ULMS), we conducted a multi-institutional survey in the Tohoku region of Japan. Methods: We conducted a retrospective cohort study between 2011 and 2014 in member institutions of the Tohoku Translational Research Center Development Network. Results: A total of 53 patients with ULMS were registered in 31 institutions for the present survey. The median patient age was 56 years, 67.9% of the patients were postmenopausal, 88.7% had a performance status of 0 or 1, and only 6 patients (11.3%) showed preoperative evidence of malignancy. Although retroperitoneal lymphadenectomy was performed in only 26.4% of patients, 64.2% patients were identified as having FIGO stage 1 disease; 73.6% were eligible to undergo complete surgery. Among 36 patients who were treated with postoperative chemotherapy, 28 (77.8%) received docetaxel and gemcitabine combination therapy. The most frequent recurrence site was the lungs, and the median progression-free survival of all enrolled patients was 11.7 months. However, the median progression-free survival and the median overall survival in patients with stages III and IV disease were 3.4 and 11.4 months, respectively. Conclusion: Although ULMS was associated with a high rate of complete or optimal surgery, the long-term prognosis was poor. Effective postoperative therapy should be developed to improve the long-term prognosis of patients with ULMS.
AB - Background: To prepare for a future clinical trial for improving the long-term prognosis of patients with uterine leiomyosarcoma (ULMS), we conducted a multi-institutional survey in the Tohoku region of Japan. Methods: We conducted a retrospective cohort study between 2011 and 2014 in member institutions of the Tohoku Translational Research Center Development Network. Results: A total of 53 patients with ULMS were registered in 31 institutions for the present survey. The median patient age was 56 years, 67.9% of the patients were postmenopausal, 88.7% had a performance status of 0 or 1, and only 6 patients (11.3%) showed preoperative evidence of malignancy. Although retroperitoneal lymphadenectomy was performed in only 26.4% of patients, 64.2% patients were identified as having FIGO stage 1 disease; 73.6% were eligible to undergo complete surgery. Among 36 patients who were treated with postoperative chemotherapy, 28 (77.8%) received docetaxel and gemcitabine combination therapy. The most frequent recurrence site was the lungs, and the median progression-free survival of all enrolled patients was 11.7 months. However, the median progression-free survival and the median overall survival in patients with stages III and IV disease were 3.4 and 11.4 months, respectively. Conclusion: Although ULMS was associated with a high rate of complete or optimal surgery, the long-term prognosis was poor. Effective postoperative therapy should be developed to improve the long-term prognosis of patients with ULMS.
KW - Retrospective survey
KW - Tohoku region
KW - Uterine leiomyosarcoma
UR - http://www.scopus.com/inward/record.url?scp=85012159752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012159752&partnerID=8YFLogxK
U2 - 10.1007/s10147-017-1097-y
DO - 10.1007/s10147-017-1097-y
M3 - Article
C2 - 28188392
AN - SCOPUS:85012159752
VL - 22
SP - 541
EP - 547
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 3
ER -